William Schuyler Jones, MD

Associate Professor of Medicine
Associate Professor in Population Health Sciences
Member of the Duke Clinical Research Institute
Campus mail 2400 Pratt Street, 7037, Durham, NC 27705
Phone (919) 668-8917
Email address schuyler.jones@duke.edu

I am an interventional cardiologist with a specific focus on the diagnosis and treatment of patients with vascular disease, and I perform coronary and peripheral angiography and interventions. I have a broad background in cardiovascular site-based research, multicenter clinical trials, clinical event classification, and observational analyses.  Currently, I am helping to lead a Duke Clinical Research Institute (DCRI) effort to coordinate a multinational, multicenter randomized clinical trial evaluating antiplatelet agents in the treatment of patients with peripheral artery disease. I have served as a physician reviewer for the
Clinical Events Classification (CEC) group at the DCRI and have been the Assistant Director of CEC since 2015. I am also the medical director of the Duke Heart Center Clinical Research Unit that manages each clinical research cluster including Cath Lab, EP, Heart Failure, General Cardiology, and Imaging.

In Their Words

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 2004 - 2005
  • Medical Resident, Medicine, Duke University, 2001 - 2004
  • M.D., University of Arkansas at Little Rock, 2001

Publications

Weissler, E Hope, Lindsay Zepel, Melissa Greiner, Bradley G. Hammill, Chandler A. Long, Manesh R. Patel, and W Schuyler Jones. “No Increase in All-Cause Mortality at 2 Years Among Patients Undergoing Drug-Coated Balloon Angioplasty.” Jacc Cardiovasc Interv 13, no. 7 (April 13, 2020): 902–4. https://doi.org/10.1016/j.jcin.2020.01.197.

PMID
32273103
Full Text

Fanaroff, Alexander C., Ghazala Haque, Betsy Thomas, Allegra E. Stone, Lynn M. Perkins, Matthew Wilson, W Schuyler Jones, et al. “Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events.” Trials 21, no. 1 (April 9, 2020): 323. https://doi.org/10.1186/s13063-020-04254-w.

PMID
32272961
Full Text

Marquis-Gravel, Guillaume, Michel Zeitouni, Ajar Kochar, W Schuyler Jones, Michael H. Sketch, Sunil V. Rao, Manesh R. Patel, and E Magnus Ohman. “Technical consideration in acute myocardial infarction with cardiogenic shock: A review of antithrombotic and PCI therapies.” Catheter Cardiovasc Interv 95, no. 5 (April 1, 2020): 924–31. https://doi.org/10.1002/ccd.28455.

PMID
31435999
Full Text

Shi, Qian, Sonali Shambhu, Amanda Marshall, Elaine Rose-Kennedy, Holly Robertson, Mark Paullin, William Schuyler Jones, Mark Cziraky, and Kevin Haynes. “Role of health plan administrative claims data in participant recruitment for pragmatic clinical trials: An Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) example.” Clin Trials 17, no. 2 (April 2020): 212–22. https://doi.org/10.1177/1740774520902989.

PMID
32009464
Full Text

Marquis-Gravel, Guillaume, Matthew T. Roe, Holly R. Robertson, Robert A. Harrington, Michael J. Pencina, Lisa G. Berdan, Bradley G. Hammill, et al. “Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial.” Jama Cardiol, March 18, 2020. https://doi.org/10.1001/jamacardio.2020.0116.

PMID
32186653
Full Text

Ward, Rachael, Zhen Huang, Frank W. Rockhold, Iris Baumgartner, Jeffrey S. Berger, Juuso I. Blomster, F Gerry R. Fowkes, et al. “Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.” Am Heart J 220 (February 2020): 51–58. https://doi.org/10.1016/j.ahj.2019.11.007.

PMID
31783279
Full Text

Windecker, Stephan, Renato D. Lopes, Tyler Massaro, Charlotte Jones-Burton, Christopher B. Granger, Ronald Aronson, Gretchen Heizer, et al. “Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.” Circulation 140, no. 23 (December 3, 2019): 1921–32. https://doi.org/10.1161/CIRCULATIONAHA.119.043308.

PMID
31557056
Full Text

Badjatiya, Anish, Peter Merrill, John B. Buse, Shaun G. Goodman, Brian Katona, Nayyar Iqbal, Neha J. Pagidipati, et al. “Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.” Circ Cardiovasc Interv 12, no. 12 (December 2019): e008018. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008018.

PMID
31752517
Full Text

Long, Chandler A., Lindsay Zepel, Melissa A. Greiner, Bradley G. Hammill, Manesh R. Patel, and W Schuyler Jones. “Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease.” Am Heart J 217 (November 2019): 42–51. https://doi.org/10.1016/j.ahj.2019.07.014.

PMID
31473326
Full Text

Pages